Product news from the 01/02/07 news brief

Share this article:
The FDA has approved Janssen’s Invega (paliperidone) extended-release tablets, a new atypical antipsychotic, for the treatment of schizophrenia. The once-daily oral medication is specifically designed to deliver paliperidone -- the active ingredient derived from risperidone -- through the innovative OROS(R) extended-release technology, demonstrating powerful efficacy and a proven safety and tolerability profile. The FDA approved BioForm Medical’s Radiesse, a cosmetic dermal filler for the long-lasting correction of moderate to severe facial wrinkles and folds. Radiesse also received FDA approval for the correction of facial fat loss in patients with HIV.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.